Document is current
Any future updates will be listed below
-
Authors
Unni, Elizabeth J.
Schougaard, Liv Marit Valen
Aiyegbusi, Olalekan Lee
Mate, Kedar K. V.
Austin, Elizabeth J.
Greffin, Klara https://orcid.org/0000-0003-0947-6091
Roberts, Natasha
Grove, Birgith Engelst
Muehlan, Holger
,
-
Funding
Funding for this research was provided by:
Universität Greifswald
- License Information
-
More Information
Article History
Received: 14 June 2024
Accepted: 28 March 2025
First Online: 9 April 2025
Declarations
:
: This study was deemed exempt by the Ethical Approval Board of the University of Washington.
: Not applicable.
: OLA receives funding from the NIHR Birmingham Biomedical Research Centre (BRC), NIHR Applied Research Collaboration (ARC), West Midlands, NIHR Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics at the University of Birmingham and University Hospitals Birmingham NHS Foundation, LifeArc, Innovate UK (part of UK Research and Innovation), The Health Foundation, Gilead Sciences Ltd, Merck, Anthony Nolan, GSK, and Sarcoma UK. He declares personal fees from Gilead Sciences, Merck, Innovate UK, Boehringer Ingelheim, and GSK outside the submitted work. The other authors declare that they have no competing interests.
